Port Moody, Canada

Mark Wood

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 5.2

ph-index = 8

Forward Citations = 310(Granted Patents)


Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Mark Wood, Pioneering Targeted Nucleic Acid Conjugate Compositions

Introduction: Mark Wood, a visionary inventor based in Port Moody, CA, has made significant contributions to the field of biopharmaceuticals through his groundbreaking work in developing targeted nucleic acid conjugates for the treatment of liver diseases. With an impressive portfolio of 16 patents, Wood continues to push the boundaries of innovation in the medical industry.

Latest Patents: Wood's latest patents showcase his expertise in developing targeted nucleic acid conjugates tailored to treat liver diseases such as hepatitis B and hepatitis D. These compositions comprise a targeting moiety, nucleic acids, and optional linking groups, providing a highly effective means of delivering therapeutic agents to the liver. By focusing on precision medicine, Wood's inventions offer promising solutions for improving patient outcomes in the realm of liver disease treatment.

Career Highlights: Throughout his career, Mark Wood has lent his expertise to esteemed companies such as Arbutus Biopharma Corporation and Xenon Pharmaceuticals Inc. His strategic insights and inventive spirit have been instrumental in driving the development of innovative pharmaceutical solutions aimed at addressing unmet medical needs. Wood's collaborative approach to research and development has earned him recognition as a trailblazer in the biopharmaceutical industry.

Collaborations: Wood has had the privilege of collaborating with accomplished professionals in the field, including James Heyes and Alan Martin. Together, they have synergized their complementary skills to advance the field of targeted nucleic acid conjugates, paving the way for novel therapeutic interventions in liver disease management. Through collaborative efforts, Wood and his colleagues have fostered a culture of innovation and excellence within the organizations they have been a part of.

Conclusion: Mark Wood's dedication to innovation and his pioneering work in developing targeted nucleic acid conjugate compositions underscore his commitment to improving healthcare outcomes for patients. By harnessing the power of precision medicine, Wood continues to make significant strides in the field of biopharmaceuticals, leaving an indelible mark on the landscape of medical innovation. His contributions serve as a testament to the transformative potential of cutting-edge research and development in revolutionizing the treatment of complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…